Brokerages expect that Agenus Inc (NASDAQ:AGEN) will announce $10.76 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Agenus’ earnings. The lowest sales estimate is $10.00 million and the highest is $11.52 million. Agenus reported sales of $3.36 million during the same quarter last year, which would suggest a positive year over year growth rate of 220.2%. The company is scheduled to issue its next quarterly earnings report on Tuesday, November 6th.
On average, analysts expect that Agenus will report full year sales of $31.33 million for the current year, with estimates ranging from $30.15 million to $32.50 million. For the next year, analysts anticipate that the firm will report sales of $10.85 million per share, with estimates ranging from $5.70 million to $16.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Agenus.
Agenus (NASDAQ:AGEN) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.16.
Several equities analysts have weighed in on the company. BidaskClub cut Agenus from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. Zacks Investment Research cut Agenus from a “hold” rating to a “sell” rating in a research note on Monday, July 23rd.
NASDAQ:AGEN remained flat at $$2.02 on Wednesday. The company’s stock had a trading volume of 725,536 shares, compared to its average volume of 1,681,640. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of -0.11. Agenus has a 52 week low of $1.55 and a 52 week high of $6.19. The stock has a market cap of $228.83 million, a PE ratio of -1.64 and a beta of 1.70.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in shares of Agenus in the 2nd quarter valued at approximately $101,000. A.R.T. Advisors LLC bought a new stake in shares of Agenus in the 1st quarter valued at approximately $103,000. MetLife Investment Advisors LLC bought a new stake in shares of Agenus in the 4th quarter valued at approximately $124,000. Russell Investments Group Ltd. bought a new stake in shares of Agenus in the 1st quarter valued at approximately $197,000. Finally, Blair William & Co. IL grew its stake in shares of Agenus by 46.6% in the 1st quarter. Blair William & Co. IL now owns 48,810 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 15,510 shares in the last quarter. 35.34% of the stock is owned by institutional investors and hedge funds.
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Featured Article: What is a Tariff?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.